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ABSTRACT 
Nanotechnology has tremendous advantages in many areas of scientific as well as clinical research. The development of nanoparticles (NPs) that 
can efficiently deliver drugs specifically to the cancer cells can help reduce normal cells toxicity and co-morbidities. Cancer can be treated by 
exploiting the unique physiochemical of the NPs, and modulating their surface modifications using ligands which further could be used as drug 
cargo vehicles. To enhance biocompatibility and drug delivery towards the target site, various modifications can be included to modify the surface of 
the NPs, such as carbohydrates, dendrimers, DNA, RNA, siRNA, drugs, and other ligands. These ligand-coated NPs have potential applications in the 
field of biomedical research, including diagnosis, contrast agents for molecular and clinical imaging (Magnetic Resonance Imaging (MRI), Computed 
tomography (CT), positron emission tomography (PET)), as cargo vehicles for drugs, increasing the blood circulation half-life, and blood 
detoxification. Further, the conjugation of anti-cancer drugs to the NPs can be efficiently used to target the cancer disease. This review highlights 
some of the features and surface modification strategies of the NPs, such as an iron oxide (IO), liposomes (LP)-based NPs, and polymer-based NPs, 
which show their effectiveness as cargo agents for cancer therapeutics.  
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INTRODUCTION 
The human body consists of trillions of cells, and each group of cells 
is designated for a specific function to sustain life. Healthy cells 
divide when they receive a chemical signal by various mechanisms, 
and the whole phenomenon is known as cell division. The cell 
division process is tightly regulated to maintain the normal 
homeostasis and is a critical issue in cancer due to the uncontrolled 
and unregulated proliferation of cell population [1]. Moreover, 
cancer cells can invade nearby tissues and get disseminated to 
distant locations in the body by the process called metastasis, 
thereby creating an unwarranted and imbalanced environment of 
normal homeostasis. The cancerous cells invade remote sites mostly 
via the bloodstream/lymphatic system, a process known as 
malignant neoplasms, which is a life-threatening situation and 
ultimately leads to death (fig. 1). The main goal of cancer treatment 
is to prevent uncontrolled cell proliferation and metastatic potential 
[2, 3]. Therefore, numerous therapeutic approaches are emerging to 
cure cancer [4, 5] based on molecular targets (receptors) such as 
overexpressed proteins and aggressive multiplication of DNA. 
Some of the approved chemotherapeutic drugs available for the 
treatment of cancer include doxorubicin (DOX), paclitaxel (PTX), 
gemcitabine, and cisplatin, to name a few. Unfortunately, 
chemotherapy in clinics fails mainly due to toxic side effects and 
their bioavailability at the different target sites other than the 
specific target site [6]. Studies on chemotherapy failure in clinics 
also suggests the diverse phenomenon of multi-drug resistance [7]. 
To overcome the limitations of bioavailability, multi-drug resistance, 
alternate treatment strategies such as radiotherapy (external beam 
therapy) and molecular radiotherapy (using beta and alpha 
radiation) are emerging in the absence/presence of various drugs in 
clinical settings [8]. Instead, radiotherapy also has few limitations 
with its side effects associated with the use of alpha and beta 
radiation. The most common side effects during the radiotherapy 
treatment include the resistance, recurrence after initial treatment, 
and tumor lysis syndrome. The treatment of cancer in the clinics has 
to be more effective in the form of specific therapy such as chemo, 
immune, and radiotherapy. For clinical validation, there is a need for 
systematic clinical trials to provide opportunities and compelling 
goals for cancer treatment. However, various difficulties or 
challenges exist while executing clinical trials, including poor study 
design, poor trial execution, patient safety, dropouts, and reduced 
patients recruitment [9, 10]. Therefore, to overcome the challenges, 
especially with the treatment modalities carried out, cargo agents 
such as NPs for specific and versatile delivery platforms are needed 
to exploit the safety, efficacy, and effectiveness of the treatment. 
These treatment modalities should have strategies that rule out the 




Fig. 1: Primary tumor and metastasis process 
 
The use of NPs in the field of nanomedicine acts as a versatile 
therapeutic platform for the synthesis and development of drug 
targeting cargos for the treatment of various types of cancers [11, 
12]. The versatility in the use of NPs depends on the use of a variety 
of materials such as metals, inorganic and organic, due to their ease 
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of synthesis, surface manipulations to carry desired functional 
groups, high binding affinity, ease of transport, which themselves act 
as therapeutic agents or carry the therapeutic agents and delivers 
especially to the tumor cells [13, 14]. NPs provide an efficient 
technology platform due to their flexibility and ease in tuning their 
biocompatible properties, synthesis of desired size and shape, 
tailoring various surface functional groups, and unique physio-
chemical features [15, 16]. The conjugation of potential 
chemotherapeutic drugs with NPs has various advantages over the 
use of chemotherapeutic drugs such as transportation, specific 
targeting ability with reduced systemic toxicity, and enhanced drug 
accumulation inside the tumor [17-19]. The surface-modified-NPs 
also increases the absorption across the epithelial distribution and 
leaky membranes in the tumor to reach the optimal concentration 
very quickly in the tumor site as compared to chemotherapeutic 
drugs when used alone.  
There are various types of NPs, such as lipid-based NPs, 
nanocapsule, polymeric NPs, metallic NPs, dendrimers, and LPs, 
emerging as useful tools in the clinical settings (fig. 2) [20, 21]. 
However, consideration of NPs based drugs in clinical practice 
remains unlikely due to various concerns such as possible toxicity 
issues, without exceptional regulatory guidance and compliance, 
cost-benefit attention, and decreasing interest for some health care 
staff. To date, different nanotechnology-based chemotherapeutic 
synthetic strategies are reported that could be considered for 
clinical use [22, 23]. Hence, we used different databases such as 
PubMed, Web of Science, Scopus, Ebesco for performing the search 
using the key terms such as lipid nanoparticles, polymeric 
nanoparticles, metallic nanoparticles, cancer, surface modifications 
to search for the relevant articles and considered.  
Types of nanoparticles 
Iron oxide (IO)-NPs 
Iron oxide NPs (IONPs) have improved super paramagnetic 
properties and are extensively considered for various clinical 
applications [24]. The different types of IO used for the NPs 
synthesis include Fe3O4 (magnetite), α-Fe2O3 (hematite or 
antiferromagnetic), c-Fe2O3 (maghemite, ferrimagnetic), FeO 
(wustite, anti-ferromagnetic), γ-Fe2O3 and β-Fe2O3. However, Fe3O4 
and γ-Fe2O3 NPs are the favorable and most commonly used 
chemical forms that are specially designed for various biomedical 
applications such as imaging contrast agents for MRI, thermal 
therapeutic tools [25, 26] and as cargo vehicles due to their features 
of improved biocompatibility and easy formulation [27-30]. These 
are structurally constituted, having nanocrystalline magnetite Fe3O4 
or γ-Fe2O3 with a polymeric coating. The Fe3O4 and γ-Fe2O3 NPs hold 
complex spinal crystal structure depending upon the cation 
distribution where oxygen ion atom occupies a tight packing in cubic 
lattice and iron ions atom positioned at interstices. Some studies 
provide insights and reveal that magnetization occurs due to the 
exchange of electrons between Fe2+ and Fe3+ atom ions that cohabit 
in the octahedral structure [31]. The properties that make the IONPs 
unique is due to their crystallizability, size, shape, super 
paramagnetic properties and magnetization induced heat 
generation. Since the size and shape of IONPs are related to their 
inherent properties, therefore synthesis is an important step. There 
are several optimized methods for the synthesis of IONPs, which 
comprise the co-precipitation, microemulsion, sonochemical 
methods, hydrothermal synthesis, and thermal decomposition. 
Furthermore, other methods of IONPs synthesis include 
electrochemical synthesis [32], laser pyrolysis techniques [33], 
microorganisms, or magnetotactic and iron-reducing bacterial 
synthesis. Considering the formulation of IONPs for clinical use is a 
significant challenging aspect. It requires specific surface 
modification that renders them high biocompatibility in the 
biological environment, reduces self-aggregation over longer 
duration preservation, reduces metal-related biological/clinical 
toxicity, multifunctional properties to hold the drugs for therapeutic 
effects and antibodies attachment for specific targeting while 
retaining the intrinsic superparamagnetic properties. The reactive 
shell properties of IONPs are used for various functional groups 
attachments such as a range of organic ligands (carboxylic acid, 
Phosphonic acid) [34, 35] polymers (PVA, PEG and PAA), sugars 
(Dextran, Chitosan) and zwitterionic ligand. 
 
 
Fig. 2: Types of NPs and their multifunctional strategies 
 
Further, other metallic/inorganic NPs (Gold, silica and Tantalum 
oxide), cross-linking besides engineering the surface coating layer is 
related to the nature of the NPs and their preferred biomedical 
applications [36, 37]. Besides, another group of researchers coated 
IONPs using small charged molecules, for example, folic acid to avoid 
macrophages uptake and enhance the heating to the cancer cell [36]. 
The in vivo kinetics and dynamics, and ultimately the fate of the 
IONPs, depends on the NPs and the type of the surface coatings, 
which determines the overall hydrodynamic size. Small NPs of 
approximately 20 nm with higher blood circulation half-life are 
usually excreted from the kidneys [38], and large NPs (150 nm) are 
quickly uptaken by the reticuloendothelial system (RES) 
predominantly by the liver and spleen. However, NPs with an 
intermediate size between 20-150 nm are mainly distributed in the 
heart, kidneys, and bone marrow [39]. 
Nanocrystalline magnetite (Fe3O4) cores have huge potential for 
biomedical applications in clinical cancer due to their properties 
that include biocompatibility, biodegradability, and simple and ease 
of synthesis [40]. There are two types of biocompatible layers that 
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can be considered to modify the surface of IONPs, i.e., organic and 
inorganic coatings [27]. The organic biocompatible based coating 
approaches are by either using a ligand exchange mechanism or 
physical assemblage/encapsulation [28]. Inorganic biocompatible 
coating involves the use of silica, Tantalum (V) Oxide. Gold NPs 
(GNPs) are inert and easily tailored by linking with the designed 
architecture of thiol (-SH) group ligands to render the best 
biocompatible properties [41]. Such types of coatings are used for 
therapeutic applications by attaching an antibody using the PEG 
linker to the Mag-GNP nanoshell [42]. IONPs coating with silica is 
performed by the Stober method or the reverse microemulsion [43]. 
The coated shells of IONPs allow performing various functions such 
as drug delivery vehicles in in vivo for the multimodal MRI and 
fluorescent imaging applications [42, 29].  
In a Fe3O4 microemulsion of tantalum (V) oxide, a sol-gel reaction was 
carried out to obtain Fe3O4/TaOx core/shell multifunctional NPs [44]. 
Upon intravenous injection, such NPs exhibit long circulation half-
lives. This rendered them as CT and MRI contrast agents to observe 
the changes associated with angiogenesis and the tumor 
microenvironment. Various researchers showed that multimeric 
ligand which can be bidentate or multidentate, for example, 
Dimercaptosuccinic acid (DMSA), containing bidentate-COOH groups 
provide excellent colloidal stability to IONPs in aqueous media and 
render water solubility and stability [43, 45]. These NPs exhibiting a 
hydrodynamic size of ~10 nm are highly stable between 6-8.5 pH 
ranges, do not self-aggregate in solution over long-standing, form 
highly homogenous solution, and are excreted by the kidneys. Natural 
ligands, like polysaccharides, can also interact with IONPs, which have 
many hydroxyl groups and carboxylic groups (-COOH), alginates, and 
amino acids [46]. Physical encapsulation of IONPs can also be achieved 
using LPs, micelles, and polymersomes via electrostatic interactions or 
van der Waals interactions. Such kind of biocompatible coatings is 
explicitly used in drug delivery for in vivo and in vitro therapeutic 
applications. Earlier anti-cancer drugs received much attention; due to 
the biocompatible nature of IONPs and are used as anti-cancer drug 
vehicles for the cancer therapeutic applications. Many anti-cancer 
drugs, for example, Doxorubicin (DOX), temozolomide (TMZ), and 
paclitaxel (PTX) are used with biocompatible coatings around IONPs 
and have been effectively validated in vitro and in vivo for their cancer 
treatment efficacy [47, 48]. 
Hequn Hao and colleagues [47] synthesized Fe3O4 nanocrystals 
using a co-precipitation technique in an alkaline medium with few 
modifications in which DOX-HCl aqueous solution was loaded onto 
Fe3O4 solution at room temperature in dark conditions followed by 
constant mixing at physiological pH for 12 h. Fe3O4 nanocrystals of 
size 10 nm were loaded onto BSA-DEX-FA NPs under high 
temperature, which triggers BSA gelation encapsulating the 
nanocrystals. Further, by diffusion technique, DOX was loaded onto 
BSA-DEX-FA, and the final formulation of NPs was obtained as 
DOX/Fe3O4/BSA-DEX-FA with an overall size of 100 nm that showed 
good solution homogeneity and stability. In vitro cytotoxicity studies 
using MTS assay in KB cells treated with DOX alone, and DOX loaded 
IONPs solutions having 1 μg/ml DOX at various intervals (24, 48 h 
and 72 h). These results showed a progressive decline in cancer cell 
proliferation in a dose and time-dependent manner. Furthermore, 
the tumor inhibition efficacy of DOX/Fe3O4/BSA-DEX-FA was 
evaluated in tumor mice models (18-22 g). Upon intravenous 
administration of DOX/Fe3O4/BSA-DEX-FA, and under the external 
magnetic field of 0.15T, the proper localization and accumulation of 
DOX loaded NPs into the tumor region was enhanced. Results 
obtained from these studies shows the tumor inhibition rate of 
about 63%, respectively. In comparison, with DOX alone, it was 55 
%, respectively.  
Temozolomide (TMZ) is a chemotherapeutic agent used for the 
management of glioblastoma. TMZ loaded IONPs functionalized with 
chitosan showed a hydrodynamic size of 50 nm [49]. Chlorotoxin 
(CTX) moieties are used as targeting ligands on these NPs. TMZ 
formulated IONPs exhibited higher stability at pH 7.4, followed by 
very long systemic circulation half-life, i.e., 7 times more than that of 
TMZ alone. A pre-clinical dose-response curve was analyzed in 
human U-118 MG cells by treatment with various concentrations (0-
200 ng/ml) of TMZ, NP-TMZ, or NP-TMZ-CTX. This study showed 
great promise to convey a remedial dosage of NP-TMZ-CTX as 
compared to TMZ alone treatment at 72 h and showed 2-6 times 
much higher uptake into the cells and 50-90% reduction in the 
tumor cell proliferation. 
Studies also suggest the preparation of IONPs using double emulsion 
capsule (DEC) stabilizers in the presence of surfactants such as PVA 
forming the DEC-IO complex. Paclitaxel (PTX) anti-cancer drug was 
loaded onto DEC-IO to form a complex of DEC-IO-PTX with a 
hydrodynamic size range of 75–200 nm. In vitro cell viability 
experiments in HeLa and MCF cells with DEC-IO-PTX treatment for 
24 h showed IC50 values of 65±7% less as compared to DEC-IO 
i.e.90±15%. They have also explored a targeting ligand like peptide 
IV024 by DEC using EDC linker against several xenograft cancer 
models of lungs, breast, prostate, liver, and oral cancer. When the cells 
were targeted using IV024 with a DOX, and PTX loaded IONPs, cell 
viability of only 10% was observed within 24 h of treatment with DOX 
and 5% with PTX in HeLa and MCF-7 cancer cells. These results explored 
the role of IV024 peptide using IONPs loaded anti-cancer agent for 
targeting the cancer cells. Similar studies were also performed using 
anti-cancer drug DOX, DEC−IO−DOX and targeting peptide ligand IV024, 
IVO24−DEC-IO−DOX, in the same cancer cells and the cell viability was 
effectively reduced with peptide ligand IV024 [50]. 
 
 
Fig. 3: IONPs and surface modifications 
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Liposome nanoparticles (LP-NPs) 
LPs are prepared from lipids, generally composed of phospholipids, 
and used as colloidal drug delivery systems [51]. LPs are chemically 
made up of phospholipids and cholesterol. Furthermore, these LPs 
have multiple concentric bilayers with each lipid bilayer separated by 
aqueous media [52]. Primarily, LPs were implied to understand the 
substantial properties of cell membranes, which include lipids 
alignment in the bilayer, their physiochemical properties, and ion 
transportation through the biological membrane. There are various 
type of LPs such as multilamellar vesicles, constituted with 
phospholipid bilayer membrane unplugged by aqueous medium up to 
5 μm size. Small unilamellar vesicle made up of aqueous partition 
enclosed with a mono lipid bilayer and the size of such LPs range from 
20-100 nm [51, 52]. We know the majority of LPs components are 
chemically phospholipids and cholesterol, which make the majority 
proportion of the biomembranes. Such chemical characteristics of 
lipids regulate the major behavior of LPs. LPs preparations involve the 
use of phospholipids and the most commonly used phospholipids 
include egg, or soya, phosphatidylcholine, and synthetic 
phosphatidylcholine [53, 54]. Since naturally occurring phospholipids 
like egg or soya bean phospholipids have a significant extent of 
polyunsaturated fatty acid, they render the vesicles less stability than 
their synthetic equivalents. The molar proportion of phospholipid 
ranges from 55 to 100 % of total LPs constituents. The 2-distearoyl-sn-
glycerophosphocholine (DSPE) is known to be the most common 
phospholipid in the LPs. The head region of DSPE is used to coordinate 
with other functional charged groups of other polymers such as 
polyethylene glycol (PEG) [55, 56]. However, phospholipid 
components alone of LPs make the sieve-like properties; therefore, the 
ratio of cholesterol determines the LPs formulation and their stability. 
The molar proportion of cholesterol, if varied between 30-45% of the 
total LPs component, determines the rigidity, elasticity, permeability, 
stability, and fluidity of the bilayer [54, 57, 58]. Furthermore, 
cholesterol also strengthens the LPs in terms of the rigidity and 
thereby influences the lipid bilayers phase transition properties. The 
increased rigidity influences encapsulated drug leakage from the 
vesicles. Some of the research groups also revealed that cholesterol 
avoids hydrolytic degradation of the lipid bilayer. Depending on the 
application of LPs, various other components also have been used in 
addition to phospholipid and cholesterol. The overall liposomal 
surface charge plays a crucial role in the cellular uptake mechanism. 
Studies show that the process of endocytosis mechanism easily takes 
positively charged or cationic LPs, whereas negatively charged and 
neutral LPs show low endocytosis uptake. However, negatively 
charged LPs are frequently used in drug delivery applications because 
negative surface charges can be recognizable by receptors present on 
various cells, including the RES. The charge on the liposomal surface 
also plays a crucial function in deciding the fate of the LPs 
intracellularly [59, 60]. While using the LPs in the clinical settings, PEG 
is the most widely used surface modifier to amplify blood circulation 
time due to its stealth properties (escaping the engulfing process and 
rapid clearance through the RES) and has demonstrated widespread 
application in the drug delivery applications for effective cancer 
treatment. The various synthetic techniques adopted for the 
preparation of LPs include-solvent removal, ethanol injection 
methods, emulsion, and detergent removal [59-61]. From these 
methods, the size distributions of LPs obtained are in the range of 25-
1000 nm depending on the LPs method adopted. However, typical 
sizes between 50 to 200 nm are commonly used for a variety of 
biomedical applications. Furthermore, we know that LPs act as a 
hydrophilic, hydrophobic, and amphiphilic carrier, and accordingly, 
the hydrophobic or hydrophilic drugs can be used to entrap or 
encapsulate within the LPs resulting in effective cancer cell 
therapeutics [53, 55]. Therefore, both hydrophobic and hydrophilic 
drugs can be used to entrap or encapsulate within the vesicles. The 
hydrophobic drug gets intercalated within the lipid layers of the LPs, 
whereas hydrophilic drugs encapsulate in the central aqueous core. 
However, the encapsulation of chemotherapeutic drugs into LPs is 
commonly brought about into two different ways (1) passive loading–
encapsulation of the drug at the time of vesicle formation and (2) 
dynamic loading–vesicle formation followed by drug trapping. LPs are 
known to be the most organic NPs approved for cancer treatment and 
usually have a great potential for targeting as delivery vehicles for 
chemotherapeutic drugs. Other applications of LPs include reduced 
transferrin (TF) elimination, enhance targeting specificity and reduce 
the chemotherapeutic agent's non-specific side effects [34, 62, 63].  
Several liposomal based drugs are now available in market such as 
Doxil/caelyx (DOX), myocet (DOX), lipodox (DOX), 
daunoxome (daunorubicin), depocytTM (cytrabin) marqibo, 
(vincristine), onco TCS (vincristine), onivyde, doceAqualip and 
visudyne. Usually, most of the liposomal formulations are used as 
intravenous injections, and their systemic administration leads to 
the rapid clearance from the circulation due which most of them 
show very short circulating half-lives. However, the circulation half-
lives could be increased, if needed, in some cases of treatment 
strategies by using branched or long chains of PEGylation. The first 
example of liposomal NPs drug is DOX-PEGylated LPs (Doxil ®), 
which has shown reduced cardiotoxic side effects [22, 64]. Doxil ® is 
approved for numerous solid tumors, such as Kaposi's sarcoma, 
ovarian cancer, multiple myeloma, and metastatic breast cancer [38, 
65]. Various studies revealed that PEGylated LPs-DOX enhances 
about 4 to 16 fold of drug efficacy in cancer cell treatment in 
comparison to free DOX. Some of the complex LPs systems have also 
been reported and are in the clinical trial. 
Cyclic RGD and TF were also used to enhance specific binding to the 
tumors and efficient cellular uptake since TF is a possible ligand for 
effective delivery as it can cross the blood-brain barrier (BBB) easily. 
Studies have shown the introduction of multiple functional groups 
onto the LPs to create RGD/TF-Lpas cargo systems. This system is 
used for linking the PTX drug to form a new complex system that 
precisely targets the gliomas. Recently, varieties of monoclonal 
antibodies have been tagged to LPs for targeting various types of 
cancer (anti-HER2 long-circulating LPs are used to target HER2-over 
expressing tumors). Antibody CC52 against an in vivo model of rat 
colon adenocarcinoma CC531 conjugated with PEGylated LPs had 
high uptake levels in cancer. Studies have also shown that i. v. 
administration of (TAG)-72 conjugated with PEG-LPs effectively 
targeted and accumulated in LS174 T human colon cancer cells [66]. 
  
 
Fig. 4: Liposome based nanoparticles 
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Polymeric based NPs 
Polymeric NPs are one of the most studied across all aspects of the 
field, including biomedical applications due to their facile synthesis 
[45, 67-70]. Polymeric NPs consist of the polymeric membrane, such 
as a hydrophilic and lipophilic surfactant. In polymeric NPs, natural 
and synthetic polymers such as N-(2-hydroxypropyl)-
methacrylamide copolymer (HPMA), Polyethylene glycol (PLGA), 
PLA, chitosan and HA are used. Recent insight revealed that natural 
and chemically modified polymeric NPs drug delivery allow more 
accurate to target specific since the coating of the NPs with polymer 
enhances the quantity of drug-loaded also help in tissue/cell-specific 
recognition proteins which leads to a more targeted and efficient 
NPs. Such NPs play a vital role as a carrier and suitable for the 
chemotherapeutic drug. Utilization of a single polymer chain of 
polymeric nanoparticle in cancer therapy provides as a therapeutic 
agent or helps in chemical modification for drug conjugation [71]. 
Poly(lactide-co-glycolic acid) (PLGA) is a synthetic polymer known 
to have outstanding properties for in vivo targeting of cancer 
because of their biodegradability and bio−compatibility properties 
[72, 73]. PLGA is a commonly used synthetic polymer and widely 
preferred for the drug-loaded NPs preparation [74, 75]. 
Furthermore, hyaluronic acid (HA) is containing negative charge and 
non-sulfated glycosaminoglycan (GAG), which is seen in connective 
tissue, neural tissue, and epithelial cells. Due to its excellent features 
such as biocompatibility, biodegradability, and non-immunogenicity, 
HA has been extensively used and widely studied for cancer 
treatment [76]. The finding from various groups also suggests that 
the PEGylated-HA NPs reduces the uptake in the liver and shows 
extended blood circulation half-lives and enhanced the tumor 
accumulation in cancer cells [77]. In vivo studies indicates that the 
PEGylated-PAC NPs loaded with DOX showed a more significant 
chemotherapeutic effect with reduced toxicity as compared to the 
DOX alone treatment [78].  
 
 
Fig. 5: Polymeric micelle 
 
Challenges 
NPs provide great opportunities in cancer therapy, leading to an 
improvement in cancer survival cases due to their high sensitivity 
and specificity. NPs based drug delivery in cancer therapy is an 
expanding field of research with the new technological 
advancements that has revolutionized medical research in the 
recent years. Though current scientific evidences shows promising 
results, however, there are few challenges of concern when it comes 
to the development of biocompatible NPs and their mode of 
treatments. Toxicity is of utmost importance and might occur due to 
various reactions taking place within the biological systems. Another 
critical challenge that limits the use of NPs-based drugs in clinical 
settings is the lack of adequate guidelines. Therefore, significant 
complications in the clinical application of nanomaterials are the 
estimation of the toxicities and mimicking the in vivo effects of 
nanoformulations. However, future advancements and research in 
this field will provide promising benefits in cancer treatment.  
CONCLUSION 
The cancer therapy that is available these days is not able to 
accurately target tumors and metastasis. Moreover, drug-resistance 
towards the clinically available and use of chemotherapeutic 
strategies is a major challenge. There is a need to develop strategies 
that could help target tumors more effectively and with reduced side 
effects. NPs such as IONPs, LPs based NPs and polymeric NPs can act 
as therapeutic tools for targeting cancers. However, the most recent 
strategies for making use of NPs as cargo agents for drug delivery in 
chemotherapeutics includes their ease of design and synthesis of 
desired sizes and shapes. The versatile nature and use of various 
types of NPs include the flexibility of surface modification by 
multifunctional agents/ligands as cargo agents for drug delivery. 
These surface-modified NPs shows potential in accumulating at the 
tumor target site (both in vitro and in vivo) with high efficacy and 
efficiency, can be modulated in the circulation for desired time 
durations and overcomes the phenomenon of drug-resistance. Such 
NPs design strategies are evolving and the recent evidences suggest 
that NPs are promising tools for cancer chemotherapeutics. 
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